Novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma Kumar, Vikas; Vardhan, Gyan; Sehrawat, Amit1; Handu, Shailendra2; Dhamija, Puneet2
Kumar, Vikas
Novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma Kumar, Vikas; Vardhan, Gyan; Sehrawat, Amit1; Handu, Shailendra2; Dhamija, Puneet2 - Vol.56(4), Jul-Sep - Mumbai Wolter Kluwer 2024 - 253-259p.
Paclitaxel is a promising anticancer drug for patients with ovarian, breast, lung, gastrointestinal, genitourinary, prostate, and head-and-neck cancers. Paclitaxel follows nonlinear pharmacokinetics. The major metabolite of paclitaxel is 6-alpha-hydroxy paclitaxel, mediated by CYP2C8, while metabolism to two of its minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’- p-dihydroxypaclitaxel, is catalyzed by CYP3A4. Therapeutic drug monitoring of paclitaxel could be a promising approach to improve the efficacy and safety of paclitaxel correct personalized doses and improve the overall benefit–risk ratio. A novel and highly sensitive chromatographic method for the detection of paclitaxel and its metabolite has been proposed that allows quantification in human plasma with 100% accuracy in terms of recovery without significant intraday or interday variations.
PHARMACOLOGY
Novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma Kumar, Vikas; Vardhan, Gyan; Sehrawat, Amit1; Handu, Shailendra2; Dhamija, Puneet2 - Vol.56(4), Jul-Sep - Mumbai Wolter Kluwer 2024 - 253-259p.
Paclitaxel is a promising anticancer drug for patients with ovarian, breast, lung, gastrointestinal, genitourinary, prostate, and head-and-neck cancers. Paclitaxel follows nonlinear pharmacokinetics. The major metabolite of paclitaxel is 6-alpha-hydroxy paclitaxel, mediated by CYP2C8, while metabolism to two of its minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’- p-dihydroxypaclitaxel, is catalyzed by CYP3A4. Therapeutic drug monitoring of paclitaxel could be a promising approach to improve the efficacy and safety of paclitaxel correct personalized doses and improve the overall benefit–risk ratio. A novel and highly sensitive chromatographic method for the detection of paclitaxel and its metabolite has been proposed that allows quantification in human plasma with 100% accuracy in terms of recovery without significant intraday or interday variations.
PHARMACOLOGY